| Document |
Document Title |
|
WO/2024/109928A1 |
Provided is a linker-containing antibody drug conjugate. Also involved are a pharmaceutical composition comprising the antibody conjugate, a use of a linker, and a use of the antibody conjugate in the preparation for a drug for preventin...
|
|
WO/2024/108811A1 |
An amino-acid-modified compound containing a pillararene structural part, a linking group with a divalent triazole ring and an amino-acid-modified group, and a method for preparing the compound and the use thereof. The amino-acid-modifie...
|
|
WO/2024/086781A3 |
According to some aspects, systems and methods for characterizing phosphoserine-containing polypeptides are described. In some embodiments, a phosphoserine residue of a polypeptide may be converted to a dehydroalanine residue. Some aspec...
|
|
WO/2024/111844A1 |
The present invention relates to a cancer-targeting peptide that can be cleaved by cathepsin B in cancer cells and is characterized by forming prodrug nanoparticles together with an anticancer agent, wherein the preparation of carrier-fr...
|
|
WO/2024/109878A1 |
Disclosed is a peptide of formula (I) R1-Ser-Pro-X1-Gln-R2, or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a salt thereof, or a composition thereof; the use thereof in the preparation of a composition for preventing...
|
|
WO/2024/106821A1 |
The peptide of the present invention has skin whitening activity due to inhibiting the incorporation of melanosomes in keratinocytes and promoting the degradation of melanosomes. The peptide of the present invention can be used as an act...
|
|
WO/2024/106586A1 |
The present application relates to a peptide having activity that promotes hair growth, and to use thereof. Provided are a peptide comprising an amino acid sequence notated as Arg-Cys-Cys-Gly or Glu-Glu, a cosmetic composition comprising...
|
|
WO/2024/106809A1 |
The present application relates to a peptide having activities to promote hair growth and ameliorate damaged hair, and use thereof and provides a peptide consisting of an amino acid sequence denoted by Arg-Cys-Cys-Gly or Glu-Glu, a cosme...
|
|
WO/2024/106924A1 |
The present invention relates to a peptidomimetic with an excellent regulatory effect on itch-inducing cytokines (TNF-α, IL-4, IL-6, and IL-8) and a composition containing same and, more specifically, to a peptidomimetic including a his...
|
|
WO/2024/106823A1 |
A peptide of the present invention has a skin whitening activity by inhibiting incorporation of melanosomes in keratinocytes, and promoting decomposition of melanosomes. The peptide of the present invention may be used as an active ingre...
|
|
WO/2024/104138A1 |
Disclosed herein are an N-terminal functionalization-modified cystyl dioleylamine compound, a chemical synthesis method therefor, and use thereof. A central skeleton of the compound is cystine; a cystine carboxyl terminal is modified wit...
|
|
WO/2024/101830A1 |
The present invention relates to an antibacterial, anti-inflammatory, or anti-acne peptide and a cosmetic composition containing same. With an acyl group of a specific compound bonded to the amine terminus of tryptophan, polytryptophan, ...
|
|
WO/2024/102986A2 |
The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.
|
|
WO/2024/101935A1 |
The present invention relates to an amphiphilic conjugate comprising a self-assemblyable peptide and use thereof. A conjugate according to one aspect and a pharmaceutical composition comprising same can be useful in the prevention or tre...
|
|
WO/2024/102639A1 |
The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant func...
|
|
WO/2024/102993A1 |
A peptide with r residues (from 4-10) that are either cationic or aromatic. The peptide has a cationic D-amino acid at the N-terminus and a cationic D-amino acid at the C-terminus. The net number of positive residues (np), is 2 ≤ np â‰...
|
|
WO/2024/094827A1 |
The present invention relates to protein ligands against Carbonic Anhydrase IX (CAIX) as target of biomedical relevance. In particular, the highly specific ligands may be able to exclusively interact with antigens expressed on the surfac...
|
|
WO/2024/097731A2 |
The invention relates to methods for treating COVID-19 by targeting the inflammasome/caspase1/pyroptosis axis as a key inflammatory pathway. In particular, the invention relates to treating a patient infected with SARS-CoV-2 with an effe...
|
|
WO/2024/094152A1 |
The present invention relates to a spiro compound, and a preparation method and use thereof. The spiro compound is as shown in formula I, has 3CL protease inhibitory activity, can effectively inhibit RNA virus replication of protein comp...
|
|
WO/2024/089049A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...
|
|
WO/2024/087332A1 |
The present invention relates to the technical field of medicines, and provides a bifunctional compound used as a target protein degradation agent and a use thereof in target protein lysosomal degradation. The bifunctional compound compr...
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/090491A1 |
The present invention provides a cell-membrane-permeable peptide for conjugation, represented by general formula (P1) [in general formula (P1): R101 is a 2-pyridyl group that may have a substituent; A1 is a cell-membrane-permeable peptid...
|
|
WO/2024/083099A1 |
Disclosed in the present invention are a drug intermediate and a preparation method therefor, and specifically disclosed are a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2024/083160A1 |
Provided are a crystal form and an amorphous substance of an indoline spiro compound represented by formula (1), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises ch...
|
|
WO/2024/086777A2 |
Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
|
|
WO/2024/084406A1 |
The invention relates to a process for synthesising acyl derivatives of glutathione and cysteine which involves considerable environmental advantages, because said compounds can be synthesised effectively without the use of environmental...
|
|
WO/2024/083164A1 |
Provided are an anisole solvate of an indoline spiro compound represented by formula (1), and a crystal form thereof, a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises c...
|
|
WO/2024/078485A1 |
The present invention belongs to the technical field of tumor immunotherapy, and specifically relates to a signal receptor used for targeting a tumor microenvironment and a cell for targeted treatment of tumors. The signal receptor compr...
|
|
WO/2024/080398A1 |
The present invention relates to a peptide having activities to promote hair growth or to prevent or inhibit alopecia. The peptide of the present invention promotes the proliferation of hair follicle dermal papilla cells (HFDPC) and huma...
|
|
WO/2024/078618A1 |
Disclosed in the present invention are a crystal form of a cyano-substituted polypeptide compound and a preparation method therefor. Specifically disclosed are a crystal form of the compound of formula (I) and a preparation method therefor.
|
|
WO/2024/079067A1 |
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2024/078294A1 |
An amorphous form of a ketoamide derivative and a preparation method therefor.The amorphous form has good stability, thus has a certain medicinal prospect, and provides a feasible active pharmaceutical ingredient for subsequent drug deve...
|
|
WO/2024/075813A1 |
Provided are: a novel diketopiperazine compound for rapid and easy synthesis of various polypeptides; and a method for manufacturing the same. The diketopiperazine compound is represented by general formula (1). (In the formula, R1, R2, ...
|
|
WO/2024/074651A1 |
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/075124A1 |
Compositions that comprise a solvent (e.g., an aqueous solvent) and a plurality of aromatic peptides that are soluble in the solvent, and non-crystalline materials formed thereof, which can be glassy and/or adhesive materials, are provid...
|
|
WO/2024/077149A2 |
Provided are crystalline forms of peptide fragments, method of preparation thereof, and use thereof for preparing peptides. The present crystalline compounds may be employed as intermediates with improved purity and physical properties f...
|
|
WO/2024/072241A1 |
The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of ovarian cancer. The invention also relates to an in vitro method for dete...
|
|
WO/2024/065056A1 |
Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound (1), via a linker. Also described are anti-cMet antibody constructs...
|
|
WO/2024/065882A1 |
An amino acid-based multifunctional water-based liquid, a preparation method therefor and a use thereof. In the water-based liquid, water is used as a solvent, and viscous droplets rich in amino acids, oligopeptides or/and amino acid/oli...
|
|
WO/2024/069524A1 |
Novel PEG modified cyclic dipeptide compounds are disclosed. The modified cyclic dipeptide compounds contain a cyclic dipeptide and a biocompatible polymer attached to the cyclic dipeptide. The cyclic dipeptide may be proline-containing,...
|
|
WO/2024/067754A1 |
The present invention relates to the technical field of medicines, and relates to an auristatin drug with a high-stability hydrophilic linking unit and a conjugate thereof. Particularly, the present invention relates to a ligand-drug con...
|
|
WO/2024/061483A1 |
The present invention relates to a tetrapeptide binding to Cholecystokinin 2 receptor (CCK-2R), wherein the tetrapeptide is represented by formula (I) Xaa1-Xaa2-Xaa3-Xaa4 (formula (I)) or salt thereof, wherein Xaa1 is Trp, (β-(3-benzoth...
|
|
WO/2024/056779A1 |
The invention relates to crystalline form of (3S,7S,10R,13R)-13-benzyl-20-fluoro-7-isobutyl-N-(2-(3-metho
xy-1,2,4- oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2
,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14- tetrade...
|
|
WO/2024/058198A1 |
Provided is a production method which is for induced pluripotent stem cells and by which induced pluripotent stem cells having high undifferentiation properties and differentiation potency are easily obtained.　A production method for i...
|
|
WO/2024/059263A1 |
The invention provides novel improved methods for preparing maytansinoid derivatives with self-immolative peptide linkers as well as their synthetic precursors.
|
|
WO/2024/059119A2 |
This invention provides compounds of formula (II) or tautomers, stereoisomers, hydrates, solvates, salts, or polymorphs thereof, wherein Z1a, X1a, Ar1, X2a, W1a, Y1a, R1a, R2a, R3a, and R4a have the same meaning as that defined in the de...
|
|
WO/2024/059754A1 |
The invention is directed to polythiolated linker compounds comprising dithiolane moieties for attaching labeled biomolecules, such as polynucleotides, to metallic particles for analysis with nanopore techniques. Further disclosed a meth...
|
|
WO/2024/052922A1 |
An isolated antibody that binds to a cyclized peptide having an amino acid sequence as set forth in SEQ ID NO: 9 with an EC50 of less than 500 nM, as determined by ELISA is disclosed. Uses of same are also disclosed as well as methods of...
|
